Omeros Co. (NASDAQ:OMER) Expected to Post Quarterly Sales of $29.29 Million

Equities analysts expect that Omeros Co. (NASDAQ:OMER) will report $29.29 million in sales for the current quarter, Zacks reports. Two analysts have provided estimates for Omeros’ earnings, with estimates ranging from $29.10 million to $29.47 million. Omeros reported sales of $26.11 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 12.2%. The firm is expected to report its next quarterly earnings results on Monday, November 8th.

On average, analysts expect that Omeros will report full year sales of $111.44 million for the current year, with estimates ranging from $110.20 million to $112.67 million. For the next fiscal year, analysts expect that the company will post sales of $148.46 million, with estimates ranging from $133.80 million to $163.11 million. Zacks’ sales averages are a mean average based on a survey of research firms that cover Omeros.

Omeros (NASDAQ:OMER) last released its earnings results on Sunday, August 8th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.50) by $0.04. The firm had revenue of $28.82 million during the quarter, compared to analysts’ expectations of $25.95 million.

A number of equities analysts have recently weighed in on OMER shares. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 price objective on shares of Omeros in a research note on Tuesday, September 7th. Zacks Investment Research lowered shares of Omeros from a “buy” rating to a “hold” rating in a research report on Friday, September 10th. Finally, WBB Securities lifted their price target on shares of Omeros from $75.00 to $100.00 and gave the company a “strong-buy” rating in a report on Friday, June 18th. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $36.67.

Large investors have recently added to or reduced their stakes in the company. Falcon Edge Capital LP bought a new position in shares of Omeros in the first quarter worth about $6,435,000. Federated Hermes Inc. bought a new position in Omeros in the 1st quarter worth about $5,283,000. Renaissance Technologies LLC purchased a new position in shares of Omeros during the second quarter worth approximately $2,924,000. Royal Bank of Canada raised its stake in shares of Omeros by 44.9% during the second quarter. Royal Bank of Canada now owns 618,776 shares of the biopharmaceutical company’s stock valued at $9,182,000 after acquiring an additional 191,610 shares in the last quarter. Finally, Voloridge Investment Management LLC purchased a new stake in shares of Omeros in the first quarter valued at approximately $3,284,000. Institutional investors and hedge funds own 51.84% of the company’s stock.

Shares of OMER traded up $0.21 during mid-day trading on Thursday, reaching $15.81. The stock had a trading volume of 13,342 shares, compared to its average volume of 588,187. The business has a fifty day moving average of $15.01 and a 200 day moving average of $16.36. The firm has a market cap of $988.06 million, a price-to-earnings ratio of -6.97 and a beta of 1.12. Omeros has a 12 month low of $9.25 and a 12 month high of $23.85.

Omeros Company Profile

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.

Read More: Day Trading – Risk Worth the Reward?

Get a free copy of the Zacks research report on Omeros (OMER)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with's FREE daily email newsletter.